American biotech companies are racing to do business with China, and for good reasons: It offers a new market for their drugs. It’s a new source of investment for nascent companies. And it’s a new place to conduct clinical trials.

But to operate in China, you need to build relationships — an exercise that can be far different than what companies experience in the United States. In interviews, experts who have actually worked in the country told STAT that they could not overestimate the importance of face-to-face meetings, how they use emails, as well as an awareness that dealmaking in China can be happen at a different pace — some things are often slower, some faster — than in the United States.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy